#esmo22 highlights on cabozantinib with nivo and ipi for intermediate/poor risk adv. rcc: cosmic-313
Published 2 years ago • 1K plays • Length 2:56Download video MP4
Download video MP3
Similar videos
-
4:01
cosmic-313: cabo nivo ipi in 1l advanced rcc of imdc intermediate or poor risk
-
1:49
cosmic-313: cabozantinib with nivolumab and ipilimumab in untreated arcc
-
4:23
esmo22: cabozantinib in combination with nivo & ipi in previously untreated arcc of imdc interme...
-
4:22
cabozantinib in combination w/ nivolumab and ipilimumab of imdc intermediate or poor risk signif...
-
1:37
esmo22 highlights: dr. jonasch discusses the cosmic313 trial for kidney cancer
-
2:30
#esmo22 highlights on first-line atezolizumab in nsclc not eligible for platinum: the ipsos study
-
4:01
nivolumab–cabozantinib boosts advanced rcc outcomes | andrea apolo
-
6:50
esmo 2022: renal roundup
-
6:26
session 5: nivolumab cabozantinib vs sunitinib for advanced rcc | checkmate9er & checkmate214
-
2:37
#esmo22 highlights on abemaciclib nsai in hr /her2- advanced breast cancer: the monarch 3 study
-
2:34
nivo cabozantinib vs sunitinib for first-line treatment of arcc
-
2:05
esmo 2020 highlights on nivolumab cabozantinib as 1st line therapy for arcc: the checkmate 9er study
-
1:05
cohort 1 litespark-003: belzutifan cabozantinib 1l treatment for advanced rcc
-
4:12
kidney cancer at esmo 2022: keynote-564 and prosper
-
33:28
esmo 2022: highlights, commentary and analysis
-
2:38
checkmate 9er: cabo-nivo superior to sunitinib in extended follow-up results
-
1:00
esmo 2022 highlights
-
2:43
cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced rcc
-
3:56
cabozantinib as immune modulatory therapy for advanced rcc